← FDA DRUG APPROVALS

FDA ANDA · ANDA076887

TERBUTALINE SULFATE

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA076887
TYPE
ANDA
ORIGINAL APPROVAL
2004-05-26
LATEST ACTION
2014-10-21
ROUTE
SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

TERBUTALINE SULFATEPrescription
TERBUTALINE SULFATE 1MG/ML · INJECTABLE · INJECTION

Approval history

2014-10-21Manufacturing (CMC) · Supplement 7AP
2011-04-08Labeling · Supplement 5AP
2004-05-26OriginalOther Important Information from FDAAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →